In Vivo Preclinical Characterization of a Novel FGFR2 Selective Inhibitor with Potency Against FGFR Activating Mutations – Cogent Biosciences

Skip to content

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

In Vivo Preclinical Characterization of a Novel FGFR2 Selective Inhibitor with Potency Against FGFR Activating Mutations

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

File size: 832.40 KB

Created: October 2022

Updated: October 2024

Hits: 20

Download Preview

Cogent Biosciences, Inc.

Massachusetts Office:
275 Wyman Street, 3^rd floor
Waltham, MA 02451

Boulder Office:
4840 Pearl E Circle, Suite 100
Boulder, CO 80301

About
Bezuclastinib
Careers
Pipelines & Research Targets
Patients & Families
Investors & Media
Legal
Privacy Policy
Cookie Notice

Scroll to Top

Scroll to Top